Sage/Biogen Zuranolone Study Shows More Efficacy, But Higher Toxicity

Commercial Prospects Still Murky

 
• By Alaric DeArment

Data from SHORELINE’s 50mg cohort sparked mixed opinions from analysts, with some suggesting they still showed a risk-benefit profile that could challenge the drug commercially.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image
Sage/Biogen released new data from the 50mg cohort of the SHORELINE study of zuranolone • Source: Shutterstock

More from Neurological

More from Therapy Areas